Vertex Pharmaceuticals (VRTX) Cash & Equivalents (2009 - 2026)

Vertex Pharmaceuticals' Cash & Equivalents history runs 18 years deep, the most recent figure standing at $5.5 billion for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 17.5% year-over-year to $5.5 billion; the TTM figure through Mar 2026 stood at $5.5 billion (up 17.5% YoY), while the FY2025 annual figure was $5.1 billion, up 11.27% from the prior year.
• Cash & Equivalents was $5.5 billion for Q1 2026 at Vertex Pharmaceuticals, up from $5.1 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $11.1 billion in Q3 2023 to a low of $4.6 billion in Q4 2024.
• Historically, Cash & Equivalents has averaged $7.4 billion across 5 years, with a median of $7.6 billion in 2022.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents soared 54.58% in 2022, then slumped 55.93% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $10.5 billion in 2022, then decreased by 1.28% to $10.4 billion in 2023, then plunged by 55.93% to $4.6 billion in 2024, then climbed by 11.27% to $5.1 billion in 2025, then increased by 8.03% to $5.5 billion in 2026.
• The last three Cash & Equivalents figures came in at $5.5 billion (Q1 2026), $5.1 billion (Q4 2025), and $4.9 billion (Q3 2025), per Business Quant data.